Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fire toxicity refers to the pathological state resulting from the inhalation of thermal and chemical products of combustion, rather than a single molecular target or receptor. It is characterized by a combination of thermal injury to the upper airways, chemical irritation of the lower respiratory tract, and systemic toxicity from asphyxiant gases such as carbon monoxide (CO) and hydrogen cyanide (HCN) [StatPearls: Inhalation Injury]. Carbon monoxide exerts its toxicity by binding to hemoglobin with an affinity 200-250 times greater than oxygen, leading to impaired oxygen delivery and cellular hypoxia [PubMed: Carbon Monoxide Poisoning]. Simultaneously, hydrogen cyanide inhibits the mitochondrial enzyme cytochrome c oxidase, effectively halting aerobic metabolism and causing rapid organ failure, particularly in the brain and heart [NIH: Cyanide Toxicity]. Because fire toxicity involves various chemical entities hitting multiple biological targets (including hemoglobin, cytochrome c oxidase, and various pulmonary surface proteins), it is considered a clinical syndrome or toxicological condition. Therapeutic intervention is diverse, targeting the specific poisons involved; for instance, inhaled beta-agonists are used to treat bronchospasm from irritants, while systemic antidotes like hydroxocobalamin are deployed for cyanide exposure. From a drug discovery perspective, 'Fire toxicity' is an incorrect designation for a target, as it represents a complex multifactorial physiological insult rather than a discrete protein, enzyme, or receptor that can be selectively modulated.
Treatment mechanisms focus on the displacement of toxic gases or the neutralization of systemic poisons. For example, high-concentration oxygen competitively displaces carbon monoxide from hemoglobin [StatPearls: Carbon Monoxide Toxicity], while hydroxocobalamin acts as a chelating agent that binds to cyanide ions to form non-toxic cyanocobalamin (Vitamin B12) [NIH: Cyanide Poisoning].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fire toxicity.